Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.

doi:10.1007/s00280-017-3481-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.

Cancer chemotherapy and pharmacology - 1 Jan 2018

Jakobsen Falk Ingrid, Lund Johan, Gréen Henrik, Gruber Astrid, Alici Evren, Lauri Birgitta, Blimark Cecilie, Mellqvist Ulf-Henrik, Swedin Agneta, Forsberg Karin, Carlsson Conny, Hardling Mats, Ahlberg Lucia, Lotfi Kourosh, Nahi Hareth

Abstract excerpt

PURPOSE: Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1 encodes the drug transporter P-glycoprotein, which confers resistance through drug extrusion across the cell membrane. Lenalidomide (Len) is excreted mainly via the kidneys, and, given the expression of P-gp in the renal tubuli, single-nucleotide polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Disease Progression

Share to Lenalidomide

Share to Multiple Myeloma

Share to Pharmacogenomic Testing

Share to Skin Diseases

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 29177954
DOI: 10.1007/s00280-017-3481-8
PMCID: PMC5754426

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.PMID 29177954Read ↗

Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.Semantic proximity Read ↗

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Semantic proximity Read ↗

Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.Semantic proximity Read ↗

ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma.Semantic proximity Read ↗

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.Semantic proximity Read ↗

CYP2C19*2 gene variant (G681A, rs4244285) as a prognostic marker for the clinical course of multiple myeloma.Semantic proximity Read ↗

Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters and survival of multiple myeloma cases in a Polish populationSemantic proximity Read ↗

Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.Semantic proximity Read ↗

Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.Semantic proximity Read ↗

Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.Semantic proximity Read ↗

A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism.Semantic proximity Read ↗

A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.